Behavioral symptoms of fragile X syndrome - A new study identifies a drug target

A recent study carried out by the team from the University of Edinburgh in the UK and McGill University in Canada which is published in the journal Cell Reports has found that an antifungal drug called cercosporamide, currently being tested as a drug candidate for the treatment of cancer showed improved behavior in mice with fragile X syndrome. It acts by blocking eIF4E activity thereby halting the excess MMP-9 protein production in mice responsible which is responsible for causing behavioral changes.

Here is the full news coverage:

A new study identifies a drug target for behavioral symptoms of fragile X syndrome -